Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

56.93 +0.08 (+0.14%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Travere Therapeutics to Present at Upcoming Investor Conferences

February 08, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February ↗

February 01, 2023

These two growth stocks might deliver enormous gains for shareholders this month.

Via The Motley Fool

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

The Latest Analyst Ratings for Travere Therapeutics ↗

January 30, 2023

Via Benzinga

4 Analysts Have This to Say About Travere Therapeutics ↗

December 05, 2022

Via Benzinga

Where Travere Therapeutics Stands With Analysts ↗

December 05, 2022

Via Benzinga

Recap: Travere Therapeutics Q3 Earnings ↗

October 27, 2022

Travere Therapeutics (NASDAQ:TVTX) reported its Q3 earnings results on Thursday, October 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA ↗

October 14, 2022

Via Benzinga

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Provides Corporate Update and 2023 Outlook

January 09, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Travere Therapeutics, Inc.

Via GlobeNewswire

Expert Ratings for Travere Therapeutics ↗

October 14, 2022

Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings:

Via Benzinga

FDA Requests For Additional Monitoring For Travere Therapeutics' Sparsentan In Rare Kidney Disease ↗

October 14, 2022

Via Benzinga

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 14, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

December 12, 2022

Monday saw 196 companies set new 52-week lows.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022 ↗

December 05, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

November 22, 2022

During Tuesday's trading, 160 companies set new 52-week lows.

Via Benzinga

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 16, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

November 15, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

November 09, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Earnings Perspective: Return On Capital Employed ↗

November 03, 2022

Benzinga Pro data, Travere Therapeutics (NASDAQ:TVTX) reported Q3 sales of $53.50 million. Earnings fell to a loss of $69.66 million, resulting in a 3.91% decrease from last quarter.

Via Benzinga

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Travere Therapeutics Reports Third Quarter 2022 Financial Results

October 27, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

October 26, 2022

Data support the Company’s lead investigational product candidate sparsentan

From Travere Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For October 27, 2022 ↗

October 27, 2022

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

Via Benzinga

Earnings Outlook For Travere Therapeutics ↗

October 26, 2022

Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Travere Therapeutics to Report Third Quarter 2022 Financial Results

October 20, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

October 13, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

121 Stocks That Hit Their 52-Week Low ↗

October 14, 2022

New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.